• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Genmab - Articles and news items

Genmab to trial daratumumab in combination with carfilzomib to treat multiple myeloma

Industry news / 17 November 2016 / Niamh Louise Marriott, Digital Content Producer

Genmab’s daratumumab (darazalex) will be investigated in a Phase III clinical study in combination with carfilzomib (kyprolis) and dexamethasone…

FDA grants priority review for Genmabs’ daratumumab to treat relapsed multiple myeloma

Industry news / 12 October 2016 / Niamh Louise Marriott, Digital Content Producer

The FDA has assigned a prescription drug user fee act (PDUFA) target date of February 17, 2017 to take a decision on daratumumab in this indication…

FDA approves Genmab’s ofatumumab for relapsed CLL

Industry news / 31 August 2016 / Niamh Louise Marriott, Digital Content Producer

Approval is supported by the Phase III complement study that evaluated ofatumumab in combination with FC versus FC alone in patients with relapsed CLL…

Genmab logo office sign

Genmab enters commercial DuoBody Technology agreement with BioNovion in the field of immuno-oncology

Industry news / 20 February 2015 / Genmab

Genmab A/S has entered a co-development and commercialisation agreement with BioNovion to evaluate a number of DuoBody product candidates targeting immune checkpoints…

Genmab logo office sign

Genmab announces preliminary results in Phase II study of Daratumumab in double refractory multiple myeloma

Industry news / 4 February 2015 / Genmab

Genmab A/S today announced preliminary results from the Phase II study of daratumumab in double refractory multiple myeloma conducted by its collaboration partner Janssen Biotech…

Genmab logo

Genmab announces new phase III combination study of Daratumumab in frontline multiple myeloma

Industry news / 10 November 2014 / Genmab A/S

Genmab A/S announced today that the French Intergroup of Myeloma (IFM) in collaboration with Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON) and Janssen Biotech, Inc. plans to start an additional Phase III study of daratumumab in frontline multiple myeloma…

GlaxoSmithKline logo

Regulatory update – GSK and Genmab announce European submission to regulatory authorities for Arzerra® (ofatumumab) as 1st line treatment of Chronic Lymphocytic Leukaemia (CLL)

Industry news / 4 October 2013 / GlaxoSmithKline

GlaxoSmithKline plc and Genmab announced the submission of a variation to the Marketing Authorisation to the European Medicines Agency (EMA) for the use of Arzerra…


Webinar: Understanding ISO Standards: ISO 14644-2:2015 Cleanroom MonitoringWATCH NOW
+ +